Tecentriq Wins Approval
The U.S. Food and Drug Administration approved Roche’s new immunotherapy drug Tecentriq to be used in non-small cell lung cancer
Read More
Part D/Prescription Drugs
Medicare shouldn’t pay more for drugs when others pay less
(By Brian C. Callaghan and Lindsey DeLott for ST A T) H illary Clinton and Donald Trump don’t see eye-to-eye
Read MoreOrgan Donation And The Opioid Epidemic: ‘An Unexpected Life-Saving Legacy’
(By Martha Bebinger, WBUR for Kaiser Health News) On the final day of June 2015, Colin LePage rode waves of
Read MoreTreat pharma as a utility, and 10 other ways states can lower drug prices
(Ed Silverman for ST A T) A s prescription drug costs continue to squeeze state budgets, a group of state
Read MoreSettlement Reached to pay $28.1 Million
Omnicare, the nation’s largest nursing home pharmacy, reached an agreement with the U.S. Department of Justice to pay $28.1 million
Read MoreMedicare Part D: A First Look at Prescription Drug Plans in 2017
(By Jack Hoadley, Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published October 17, 2016) During the Medicare open
Read MoreHere are 3 big projects the White House cancer moonshot is pursuing
(By Dylan Scott for ST A T) L iquid biopsies. A “groundbreaking” Defense Department study. Partnerships with Lyft and Uber
Read More7 Insurers Alleged To Use Skimpy Drug Coverage To Discourage HIV Patients
(By Michelle Andrews for Kaiser Health News) The health law prohibits insurers from discriminating against people with serious illnesses, but
Read MoreWhat side effects? Most consumers don’t read drug risk information
(By Ed Silverman for ST A T) H ow much attention do people pay to the risk information for prescription
Read MoreInsurers pay more for multiple sclerosis drug because rebates don’t help, report says
(By Ed Silverman for ST A T) D rug makers may offer rebates to payers, but health plans continue to
Read More